American Century Companies Inc. decreased its stake in Eli Lilly and Co (NYSE:LLY) by 31.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,527,509 shares of the company’s stock after selling 715,357 shares during the period. American Century Companies Inc.’s holdings in Eli Lilly and were worth $129,013,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of LLY. Beach Investment Management LLC. bought a new position in Eli Lilly and in the 2nd quarter valued at approximately $400,000. Alps Advisors Inc. lifted its stake in Eli Lilly and by 3.4% in the 2nd quarter. Alps Advisors Inc. now owns 578,098 shares of the company’s stock valued at $47,577,000 after purchasing an additional 19,110 shares during the last quarter. Legal & General Group Plc lifted its stake in Eli Lilly and by 2.8% in the 2nd quarter. Legal & General Group Plc now owns 5,101,196 shares of the company’s stock valued at $419,840,000 after purchasing an additional 136,660 shares during the last quarter. BARING ASSET MANAGEMENT Ltd bought a new position in Eli Lilly and in the 2nd quarter valued at approximately $1,668,000. Finally, Highstreet Asset Management Inc. bought a new position in Eli Lilly and in the 2nd quarter valued at approximately $814,000. 76.45% of the stock is owned by institutional investors and hedge funds.

In related news, insider Donald A. Zakrowski sold 900 shares of Eli Lilly and stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now owns 4,130 shares of the company’s stock, valued at $334,901.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jeffrey N. Simmons sold 12,500 shares of Eli Lilly and stock in a transaction on Monday, December 11th. The stock was sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the transaction, the senior vice president now directly owns 124,522 shares of the company’s stock, valued at approximately $10,766,172.12. The disclosure for this sale can be found here. Insiders have sold 259,610 shares of company stock valued at $22,727,406 in the last three months. 0.20% of the stock is owned by insiders.

Several equities analysts recently commented on the stock. Leerink Swann raised their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, October 24th. Goldman Sachs Group downgraded shares of Eli Lilly and from a “buy” rating to a “neutral” rating and raised their price target for the company from $86.98 to $95.00 in a research note on Tuesday, January 16th. Jefferies Group set a $100.00 price target on shares of Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Finally, Credit Suisse Group reaffirmed a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $92.02.

Eli Lilly and Co (NYSE:LLY) opened at $74.21 on Friday. Eli Lilly and Co has a 52 week low of $74.19 and a 52 week high of $89.09. The firm has a market cap of $81,710.00, a price-to-earnings ratio of -371.05, a P/E/G ratio of 1.43 and a beta of 0.23. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The business had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. During the same quarter last year, the firm earned $0.95 earnings per share. Eli Lilly and’s quarterly revenue was up 7.0% on a year-over-year basis. analysts expect that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is currently -1,040.00%.

WARNING: “American Century Companies Inc. Reduces Position in Eli Lilly and Co (LLY)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2018/02/09/american-century-companies-inc-reduces-position-in-eli-lilly-and-co-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.